Product Name:    Dapagliflozin propanediol monohydrate

Synonyms:    (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL COMPOUND WITH (S)-PROPANE-1,2-DIOL (1:1) HYDRATE;BMS 512148 (2S)-1,2-propanediol;CS-1307;Dapagliflozin (S)-Propylene Glycol Hydrate;Dag column net a water glycol;Dapagliflozin propanediol hydrate;Dapagliflozin,(2S)-1,2-propanediol, hydrate (1:1:1);Dapagliflozin ((2S)-1,2-propanediol, hydrate)###461432-26-8###Dapagliflozin

CAS:    960404-48-2

MF:    C24H33ClO8

MW:    484.97

EINECS:    811-335-4

Dapagliflozin propanediol monohydrate is the first approved sodium-glucose cotransporter protein 2 (SGLT2) inhibitor. It is indicated for the treatment of type 2 diabetes. When combined with diet and exercise in adults, dagliflozin helps improve glycaemic control by inhibiting glucose reabsorption in the proximal tubules of renal units and causing glycosuria. Dagliflozin can be given alone or in combination with insulin or other oral hypoglycaemic agents as adjunctive therapy.

Dagliflozin was originally approved by the FDA on 8 January 2014 for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It was later approved in April 2021 to reduce the risk of declining kidney function, kidney failure, cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease.